Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of padsevonil as adjunctive treatment for focal-onset seizures in drug-resistant epilepsy
jRCT2080224540Phase 3Completed
- Sponsor
- UCB
- Start
- Jan 2019
- Modality
- Small Molecules
01
Overview
Phase 3, open-label, single-arm trial of padsevonil in refractory focal epilepsy, sponsored by UCB. Started Jan 2019; status: completed.
02
Drugs
padsevonil
03
Conditions
refractory focal epilepsy
Beyond the preview
Go deeper on jRCT2080224540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224540.